Thyroid metastases represent spread of a malignant tumor from another organ to the thyroid gland. Although thyroid metastases are found in 1.25-24% of patients with widespread cancer at autopsy, clinically significant thyroid metastasis is rare, constituting 1-3% of all thyroid malignancies. The most common primary sources are renal cell carcinoma (clear cell type), lung carcinoma, breast carcinoma, and melanoma. Renal cell carcinoma is the most frequent cause of thyroid metastases (23-50%) — its rich vascularity and the high blood flow of the thyroid gland explain this tropism. Thyroid metastases may appear as solitary or multiple nodules; bilateral involvement is a finding favoring metastasis. They can appear years after the primary tumor diagnosis (even 10+ years later in RCC). Diagnosis can be made by FNA but comparison with primary tumor histology is required.
Age Range
40-80
Peak Age
60
Gender
Equal
Prevalence
Rare
The thyroid gland has one of the highest blood flows relative to body weight (4-6 mL/g tissue per minute) — this intense perfusion creates a favorable environment for hematogenous metastases. Several mechanisms underlie RCC's thyroid tropism: RCC cells have high angiogenesis capacity due to high VEGF expression, and the thyroid gland's rich capillary network provides an ideal microenvironment for these cells to implant and grow. Additionally, the thyroid's high iodine concentration may support tumor growth. Metastatic nodules generally preserve the histological features of the primary tumor — RCC metastases maintain the hypervascular, clear cell appearance, which causes prominent enhancement on imaging. Melanoma metastases may contain melanin pigment and show high signal on T1-weighted MRI due to paramagnetic melanin. Lymphatic spread is less common; usually seen in head-neck tumors (larynx, pharynx SCC). Multiple bilateral nodules suggest hematogenous spread while solitary nodules may be confused with primary thyroid carcinoma.
Bilateral, prominently hypervascular enhancing thyroid nodules in a patient with known malignancy (especially RCC) history — a combination highly suspicious for metastasis. RCC's intense vascularity is preserved in the metastatic site and manifests as prominent arterial enhancement. Since bilateral involvement is much rarer in primary thyroid carcinomas, this pattern strongly supports metastasis.
Solid, hypoechoic nodule(s) on ultrasonography — solitary or multiple, unilateral or bilateral. RCC metastases are generally well-defined, homogeneously hypoechoic. Melanoma metastases may be heterogeneous with irregular margins. Breast and lung metastases appear as irregularly margined, heterogeneous hypoechoic nodules. Bilateral multiple nodules are a strong finding favoring metastasis. Nodules generally do not contain microcalcifications (distinguishing from papillary carcinoma).
Report Sentence
Solid, hypoechoic nodule(s) measuring ... mm are seen in the [right/left/bilateral] thyroid lobe(s); considering the patient's known history of [RCC/lung/breast/melanoma], metastasis should be primarily considered in the differential diagnosis.
Prominent intranodular hypervascularity on color Doppler — particularly marked in RCC metastases. Vascular pattern is chaotic with dense intranodular flow. Due to RCC's high VEGF expression, intense neovascularization occurs in the metastatic area. This finding is important before FNA or biopsy — bleeding risk is increased during biopsy of hypervascular nodules.
Report Sentence
The thyroid nodule demonstrates prominent intranodular hypervascularity on color Doppler, a pattern consistent with RCC metastasis; bleeding risk should be considered before FNA.
Prominently hypervascular enhancing nodule on arterial phase contrast-enhanced CT — may be considered pathognomonic especially in RCC metastases. The nodule may enhance more intensely than normal thyroid parenchyma. Relative washout may be seen in the portal venous phase. May present as bilateral multiple nodules. Lung and breast metastases are less vascular and show mild-to-moderate enhancement.
Report Sentence
Prominently hypervascular enhancing ... mm nodule(s) are seen in the [right/left/bilateral] thyroid lobe(s) on arterial phase contrast-enhanced CT; considering the patient's known history of renal cell carcinoma, findings are consistent with metastasis.
Melanoma metastases show intrinsic high signal (hyperintensity) on T1-weighted MRI images — due to the paramagnetic property of melanin pigment. This finding is highly characteristic of melanoma metastasis and is not seen in other thyroid tumors. Amelanotic melanoma metastases may not show this feature. RCC metastases show intermediate T1 signal, may show focal high signal if containing subacute hemorrhage.
Report Sentence
The thyroid nodule demonstrates intrinsic high signal on T1-weighted sequences, consistent with melanoma metastasis due to paramagnetic melanin deposition.
Metastases generally show diffusion restriction on DWI but ADC values vary according to primary tumor type. RCC metastases may show higher ADC values (clear cell architecture, less dense packing). Melanoma and small cell lung carcinoma metastases show lower ADC values. DWI helps distinguish metastatic nodules from benign nodules but is limited in determining the specific primary source.
Report Sentence
The thyroid nodule(s) demonstrate diffusion restriction on diffusion-weighted imaging with ADC values of ... × 10⁻³ mm²/s; consistent with metastasis in the context of known malignancy history.
The thyroid nodule(s) demonstrate increased FDG uptake on FDG PET-CT. SUVmax varies depending on primary tumor type. The main value of PET-CT is evaluating the extent of systemic metastatic disease — detection of metastatic sites outside the thyroid changes treatment planning. Incidentally detected focal thyroid FDG uptake during known malignancy surveillance may be malignant in 30-40% of cases.
Report Sentence
Focal increased FDG uptake is seen in the [right/left/bilateral] thyroid lobe(s) on FDG PET-CT (SUVmax: ...); consistent with metastasis in the context of known [primary tumor] history; metastatic foci in other organs should also be simultaneously evaluated.
Criteria
Most common source of thyroid metastasis (23-50%). Clear cell type most common. Can appear even 10+ years after primary tumor diagnosis (late recurrence). PAX8+, CD10+, RCC marker+ immunohistochemistry.
Distinct Features
Prominent hypervascular enhancement (intense in arterial phase). Intranodular hypervascularity on Doppler. Clear cell morphology on FNA. Cold nodule on scintigraphy.
Criteria
Comprises 8-15% of thyroid metastases. Melanotic and amelanotic forms exist. Appears in the context of widespread metastatic disease. S100+, HMB45+, Melan-A+ immunohistochemistry.
Distinct Features
T1 hyperintense signal (paramagnetic melanin) — absent in amelanotic form. Heterogeneous enhancement. Pigmented cells on FNA. Marked diffusion restriction on DWI.
Criteria
Comprises 15-20% of thyroid metastases. Small cell and non-small cell types. Usually in context of advanced lung carcinoma. TTF-1+, Napsin-A+ (adenocarcinoma) immunohistochemistry.
Distinct Features
Irregularly margined, heterogeneous hypoechoic nodule. Moderate enhancement. TTF-1 positivity can also be seen in thyroid primary carcinoma — Napsin-A and thyroglobulin are used for differentiation (thyroid primary: thyroglobulin+, lung metastasis: Napsin-A+).
Distinguishing Feature
Papillary carcinoma shows microcalcifications, taller-than-wide shape, irregular margins. Metastasis generally does not contain microcalcifications and bilateral involvement is more common. Clinical history (known malignancy) and immunohistochemistry (thyroglobulin for primary thyroid carcinoma, PAX8/CD10/TTF-1 for metastasis) are distinguishing.
Distinguishing Feature
Follicular carcinoma is typically a solitary, well-defined nodule with thick halo. RCC metastasis may also be well-defined but hypervascularity is much more prominent. Bilateral involvement and known malignancy history support metastasis. Immunohistochemistry on FNA is distinguishing.
Distinguishing Feature
MTC shows coarse calcifications (amyloid deposition), serum calcitonin is elevated. Calcification is rare in metastases (calcified metastasis is the exception), calcitonin is normal. Clinical history and immunohistochemistry are distinguishing.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralWhen thyroid metastasis is detected, multidisciplinary oncological evaluation is required. Tissue diagnosis should be obtained by FNA and compared with primary tumor histology — immunohistochemistry panel (PAX8, CD10, TTF-1, thyroglobulin, S100, HMB45, Napsin-A) should be applied. Extent of systemic metastatic disease should be evaluated with PET-CT or whole-body CT. In isolated thyroid metastasis (rare), thyroidectomy may be curative — especially in RCC metastasis, long-term survival can be achieved. In widespread metastatic disease, treatment is systemic therapy directed at the primary tumor. Since RCC metastasis is hypervascular, bleeding risk should be assessed before biopsy/surgery.
Thyroid metastasis is usually part of widespread metastatic disease. FNA can detect cytological features of the primary tumor (immunohistochemistry critical). Treatment is directed at the primary disease. Surgery may be considered for isolated thyroid metastasis.